Compare Expensify Inc (EXFY) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Tilray Brands Inc — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while Tilray Brands Inc trades at $3.5 (market cap $530.54M). The key difference: Tilray Brands Inc is far larger — about 2.5× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Tilray Brands Inc for 31 Days on average.
| EXFY | TLRY | |
|---|---|---|
Market Cap | $208.82M | $530.54M |
Volume | 456,102 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $2.72 | $21.00 |
52-Week Low | $0.75 | $3.57 |
Typical Hold Time | 41 Days | 31 Days |
Enterprise Value | $148.44M | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.37, up 4.41% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with a high P/E ratio of 258.82 but improving cash flow trends, with Q2 2026 earnings beating expectations. Recent news highlights strategic integrations with AI-native ERP platforms and European expansion of its corporate card offering, signaling growth initiatives.
The outlook remains speculative with analyst consensus bullish (50% buy ratings) and a $13.75 price target, but negative net income margins and competitive pressures pose risks. Investment opportunity hinges on successful execution of AI-driven products and international growth, while downside risks include sustained profitability challenges and market volatility.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
